Connor Clark & Lunn Investment Management Ltd. Sells 48,460 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Connor Clark & Lunn Investment Management Ltd. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 7.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 633,864 shares of the biotechnology company’s stock after selling 48,460 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.31% of BioCryst Pharmaceuticals worth $4,767,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in BCRX. Venturi Wealth Management LLC acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $46,000. R Squared Ltd acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $48,000. KBC Group NV boosted its position in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 4,537 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $80,000. Finally, Quantinno Capital Management LP acquired a new stake in BioCryst Pharmaceuticals in the third quarter valued at approximately $82,000. 85.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on BCRX. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Royal Bank of Canada restated an “outperform” rating and issued a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Needham & Company LLC raised their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Evercore ISI lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Wedbush began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Stock Up 2.1 %

BCRX stock opened at $7.70 on Monday. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -12.62 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $9.50. The company’s fifty day simple moving average is $8.14 and its 200 day simple moving average is $7.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.28 EPS. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.